DUBLIN, Sept. 12, 2018 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today announced the launch of Spotlyte™ – an
innovative digital hub of curated content that helps consumers
discover how medical aesthetic treatments may fit into their
routines. Through well-researched content, product reviews and
insider profiles, together with the latest beauty news and trends,
the site functions as a holistic and informative lens into these
worlds. Beyond the editorial, Spotlyte will provide access
to a team of trained specialists ready to offer
real-time support and chat directly with anyone considering medical
aesthetic treatments, as well as help connect readers to local
licensed providers.
Led by Alexandra Wilkis Wilson,
co-founder of Gilt Groupe® and
Glamsquad®, and appointed senior vice
president of Consumer Strategy and Innovation at Allergan, Spotlyte
is the first venture from the new Allergan-owned digital ventures
unit, Project Moonwalker™. Dedicated to creating consumer facing
businesses that unlock opportunities in the medical aesthetics
category, Project Moonwalker will serve as a launchpad for new
innovations that capitalize on a growing market.
"We have a unique position as industry leaders to identify
emerging trends in real time and change the way that consumers
engage with medical aesthetics," said Alexandra Wilkis Wilson. "I have spent most of
my career focused on the consumer while creating powerful brands at
the intersection of technology and lifestyle. The core goal of
Project Moonwalker is to enable information flow and access.
Spotlyte is the first step in changing how consumers can become
better educated on medical aesthetics."
Consumers seek more information and don't always know where to
go or who to trust. There are over 65 million Americans considering
a variety of medical aesthetic treatments (from facial injectables
to body contouring and breast implants) with approximately 30%
citing lack of information as the top barrier to conversion.
Allergan sees a huge opportunity to propel the aesthetics market
forward by going direct to consumers.
"As the market leader in medical aesthetics, we have the
opportunity and the responsibility to properly educate consumers
and mainstream the conversation around aesthetic treatments. We
want to create an open dialogue by incorporating medical aesthetics
into the overall aesthetics conversation," said Brent Saunders, CEO of Allergan. "We believe the
medical aesthetics market will double in 5-7 years."
The site is brand agnostic, with the goal of educating consumers
and providing well researched and accurate information on medical
aesthetics. For those who are curious or want to learn more, the
on-site chat feature connects consumers to a specialist who will
offer information and help make connections to local licensed
providers.
For the latest news or more information, visit
www.thespotlyte.com or follow the site on Instagram @Spotlyte.
All trademarks are the property of their respective owners.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical leader. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues'
commitment to being Bold for Life. Together, we build bridges,
power ideas, act fast and drive results for our customers and
patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated
with divestitures, acquisitions, mergers and joint ventures;
uncertainty associated with financial projections, projected cost
reductions, projected debt reduction, projected synergies,
restructurings, increased costs, and adverse tax consequences;
difficulties or delays in manufacturing; and other risks and
uncertainties detailed in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not limited
to Allergan's Annual Report on Form 10-K for the year ended
December 31, 2017 and Allergan's
Quarterly Report on Form 10-Q for the period ended June 30, 2018. Except as expressly required by
law, Allergan disclaims any intent or obligation to update these
forward-looking statements.
CONTACTS:
Allergan:
Investors:
Daphne Karydas
(862) 261-8006
Karina Calzadilla
(862) 261-7328
Media:
Amy Rose
(862) 289-3072
Amanda Rosenberg
(917) 415-2726
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-unveils-spotlyte-a-first-in-category-digital-hub-designed-to-educate-consumers-about-medical-aesthetic-treatments-300710492.html
SOURCE Allergan plc